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PEMBANGUNAN FORMULASI BAGI EKSTRAK EURYCOMA 
LONGIFOLIA DAN PHYLLANTHUS NIRURI UNTUK KAJIAN 
FARMAKOKINETIK DAN BIOKEPEROLEHAN 
 
ABSTRAK 
 
Ekstrak Phyllanthus niruri yang kaya dengan lignan (PNF5) menormalkan asid urik 
plasma tikus hiperurisemik, dan kesannya adalah setanding dengan allopurinol yang 
digunakan secara klinikal. Ekstrak Eurycoma longifolia (TAF2) yang kaya dengan 
kuassinoid dapat meningkatkan jumlah sperma tikus jantan secara signifikan, dan 
mempunyai potensi yang tinggi untuk merawati kemandulan lelaki. Namun demikian, 
biokeperolehan oral bagi lignan, phyltetralin (PT) dan phyllanthin (PL), dalam PNF5 
dan kuassinoid, 13α(21)-epoxyeurycomanon (EP) dan eurycomanon (EN) adalah 
sangat rendah kerana keterlarutan lignan yang rendah dalam air dan kebolehtelapan 
membran yang rendah bagi kuassinoid. Kajian ini telah meningkatkan 
biokeperolehan oral PT dan PL dalam PNF5, dan EP dan EN dalam TAF2 yang 
dimasukkan ke dalam sebaran pepejal berdasar Gelucire 44/14 (SDC). Kajian in vitro, 
iaitu ujian pelarutan dan kaedah kantung usus tikus dalam ke luar, telah 
menunjukkan bahawa pelarutan dan kebolehtelapan PT dan PL dalam PNF5-SDC 
dan kebolehtelapan membran EP dan EN dalam TAF2-SDC dapat ditingkatkan 
berbanding dengan formulasi konvensional kapsul berisi serbuk (PFC). 
Parameter-parameter farmakokinetik bagi PT, PL, EP dan EN menunjukkan bahawa 
kadar pergerakan sebatian-sebatian ini dari bahagian pusat ke periferi adalah 
perlahan berbanding dengan kadar pergerakannya dari bahagian periferi ke pusat (P < 
 xxx 
0.001). Kadar pengagihan sebatian-sebatian ini adalah lebih cepat (P < 0.001) 
berbanding dengan kadar penyingkiran. Justeru itu, farmakokinetik in vivo bagi PT, 
PL, EP dan EN itu digambarkan sebagai proses dwi-kompartmen. Kajian in vivo 
dalam tikus menunjukkan bahawa, biokeperolehan oral relatif PT dan PL dalam 
PNF5-SDC telah meningkat sebanyak 3 kali ganda, berbanding dengan PFC, 
manakala EP dan EN dalam TAF2-SDC telah meningkat sebanyak 1.7 kali dan 2.8 
kali ganda masing-masing. Namun begitu, biokeperolehan mutlak bagi 
sebatian-sebatian yang dikaji dalam PNF5 dan TAF2 masih lagi rendah. Hasil 
daripada kajian in vitro menggunakan kantung usus tikus dalam ke luar dan kaedah 
pengeraman homogenate hati dan pemberian ketokonazol secara in vivo kepada tikus 
Sprague Dawley (SD), telah menunjukkan bahawa biokeperolehan mutlak yang 
rendah bagi PT dan PL dalam PNF5 berkemungkinan besar disebabkan oleh PT dan 
PL yang bertindak sebagai substrat dalam efluks P-gp. Penyerapan oral bagi EP dan 
EN dalam TAF2 pula didapati tidak dipengaruhi oleh efluks P-gp dan metabolisme 
CYP3A4. Disamping itu, fenomena puncak berganda juga dikesan dalam profil 
farmakokinetik bagi EP dan EN dalam sebaran pepejal TAF2. Kajian in vivo yang 
menggunakan tikus SD telah menunjukkan bahawa kelewatan dalam masa 
pengosongan gastrik dan penyerapan kolon telah mengakibatkan penghasilan 
fenomena puncak berganda pada farmakokinetik kuassinoid dalam sebaran pepejal 
TAF2. 
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DEVELOPMENT OF FORMULATED EURYCOMA LONGIFOLIA AND 
PHYLLANTHUS NIRURI EXTRACTS FOR PHARMACOKINETIC 
AND BIOAVAILABILITY STUDIES 
 
ABSTRACT 
 
The lignan-rich extract of Phyllanthus niruri (PNF5) normalises the plasma uric acid 
of hyperuricemic rats, and its effects are comparable to those of clinically used 
allopurinol. The quassinoid-rich extract of Eurycoma longifolia (TAF2) significantly 
improves the sperm count of male rats, and may be potentially suitable for managing 
male infertility. However, the oral bioavailability of the bioactive lignans, 
phyltetralin (PT) and phyllanthin (PL), in PNF5 and the quassinoids, 
13α(21)-epoxyeurycomanone (EP) and eurycomanone (EN), in TAF2 were low due 
to the low aqueous solubility of the lignans and poor membrane permeability of the 
quassinoids. The present study led to the improvement of the oral bioavailabilities of 
PT and PL in PNF5, and EP and EN in TAF2 through incorporation in a 
Gelucire
®
44/14-based solid dispersion (SDC). In vitro studies, which were 
dissolution test and everted rat gut sac method indicated that PNF5-SDC formulation 
resulted in higher release of PT and PL, and TAF2-SDC resulted in higher 
permeation of EP and EN compared to the conventional powder-filled capsules (PFC) 
formulations. The pharmacokinetic parameters of PT, PL, EP and EN indicated that 
the rate of these compound movements from the central compartment to peripheral 
compartment were slow compared to the rate movement from the peripheral 
compartment to the central compartment (P < 0.001).  The distribution rates of these 
 xxxii 
compounds were much faster (P < 0.001) than the elimination rates. The in vivo 
pharmacokinetics of PT, PL, EP and EN were thus being described as 
two-compartment process. The in vivo study in rats showed that the relative oral 
bioavailabilities of PT and PL in the PNF5-SDC increased by 3-fold compared to 
those in PFC, while the EP and EN in TAF2-SDC improved by 1.7-fold and 2.8-fold, 
respectively. However, the absolute bioavailabilities of the studied compounds in 
PNF5 and TAF2 were still low. The results from studies using the in vitro everted gut 
sac method and liver homogenate incubation method, and in vivo administration of 
ketoconazole to Sprague Dawley (SD) rats, revealed that the low oral absolute 
bioavailabilities of PT and PL in PNF5 were most likely due to PT and PL acting as 
substrates for P-gp efflux. On the other hand, the oral absorptions of EP and EN in 
TAF2 were not affected by P-gp efflux and CYP3A4 metabolism. In addition, a 
double peak phenomenon was also identified in the pharmacokinetic profiles of EP 
and EN in TAF2 solid dispersion. The result of an in vivo study using SD rats 
indicated that delayed gastric emptying time and colonic absorption accounted for 
the establishment of the double peak phenomenon observed for the pharmacokinetics 
of the quassinoids in the TAF2 solid dispersion.  
 
 
 1 
CHAPTER ONE:  General introduction 
  
1.1 Hyperuricemia and Phyllanthus niruri 
 
1.1.1 Hyperuricemia and medicinal approaches. 
Purines are heterocyclic aromatic organic compounds consisting of a pyrimidine ring 
fused to an imidazole ring. Catabolism of purine nucleotides ultimately leads to the 
production of uric acid, which is sparingly soluble in extracellular body fluids. The 
concentration of uric acid generally almost reaches the saturation level in the 
extracellular body fluids. Therefore, a slight change in this saturation level by purine 
metabolism may cause uric acid precipitation (Pennes and Martel, 1986). It was 
reported that the imbalance in the excretion and production rate of uric acid causes 
hyperuricemia which in turn results in gout (Sherman et al., 2008). 
 
Currently, the clinical approaches for drug treatment of hyperuricemia are very 
limited (Murugaiyah and Chan, 2006). Allopurinol, benzbromarone, and probenecid 
are generally used in clinical treatments. Allopurinol is mostly used, but is associated 
with adverse drug reactions (Khoo and Leow, 2000). Some natural plants, such as 
Larix laricina (Owen and Johns, 1999), Cinnamomum cassia, Polygonum 
cuspidatum (Kong et al., 2000) and Chrysanthemum sinense (Nguyen et al., 2004) 
were reported to exhibit anti-hyperuricemic activity. Recently, a Malaysian plant, 
Phyllanthus niruri, was found to exhibit anti-hyperuricemic activity (Murugaiyah 
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and Chan, 2006). 
 
1.1.2 Phyllanthus niruri 
 
1.1.2 (A) Botanical aspects and traditional usage 
Phyllanthus niruri L. (Euphorbiaceae) is known locally as “dukong anak.” 
Phyllanthus has about 750 species (Hnatyszyn et al., 1999). Phyllanthus niruri is the 
most widely used plants of the Phyllanthus genus because of its worldwide 
distribution (Calixto et al., 1998). P. niruri is an annual glabrous herb that grows 
from 30 to 60 cm (Wright et al., 2007), and has small leaves and small off-white-
greenish flowers (Bagalkotkar et al., 2006). P. niruri is very similar to P. amarus in 
appearance and chemical content, but recent studies have indicated that they are 
different but are very close species (Lee et al., 2006). The plant has been traditionally 
used as expectorant, anti-febrile, anti-diarrhoea, diuretic, and a remedy for colic and 
kidney problems (Murugaiyah and Chan, 2007, Wright et al., 2007). 
 
1.1.2 (B) Chemical constituents and activities. 
 Several chemical constituents isolated from P. niruri, include alkaloids 
(Mulchandani and Hassarajani, 1984, Joshi et al., 1986, Petchnaree et al., 1986), 
benzenoids, coumarins (Ueno et al., 1988, Shimizu et al., 1989), flavonoids 
(Chauhan et al., 1977, Nara et al., 1977, Gupta and Ahmed, 1984b, a), lipids (Ahmad 
et al., 1981), phytallates (Singh et al., 1986), sterols (Mannan and Ahmad, 1976), 
 3 
tannins (Ueno et al., 1988), triterpenes (Chauhan et al., 1979, Singh et al., 1989a, b), 
and lignans (Row et al., 1966, Anjaneyulu et al., 1973, Ganeshpure et al., 1981, 
Huang et al., 1992). Some of these compounds were found to possess 
pharmacological activities. Rutin has anti-inflammatory and analgesic functions 
(Santos et al., 1995, Santos et al., 1996). Ellagic acid was found to be an aldose 
reductase inhibitor (Shimizu et al., 1989). Geraniin is an ACE inhibitor, anti-allergy, 
and analgesic (Ueno et al., 1988). Quercetin has properties of an inhibitor of 
mitochondrial ATPase, phosphodiesterase, phosphorilase and tirosine kinase, and 
phopholipase A2. Niruside was found to be anti-HIV (Hussain et al., 1995). 
Repandusinic acid A, phillanthin, hypophillanthin, and hirtetralin were found to be 
anti-HIV, anti-hepatoxic, and are endothelin antagonists (Syamasundar et al., 1985). 
Phyllanthin and hypophyllanthin protected carbon tetrachloride- and galactosamine-
induced cytotoxicity in primary cultured rat hepatocytes. Triacontanal was protective 
against galactosamine-induced toxicity (Syamasundar et al., 1985). As a 
hepatoprotective herbal plant, the potential of the protein isolates from P. niruri was 
investigated against carbon tetrachloride (CCl4)-induced hepatoxicity (Bhattacharjee 
and Sil, 2007). 
 
1.1.2 (C) Toxicity and safety 
Some toxicity studies of P. niruri and its compounds have been studied, but the 
lignans in P. niruri demonstrated no significant cytotoxic activity when evaluated 
against several cultured mammalian cells (Somanabandhu et al., 1993). Recently, P. 
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niruri MeOH extract was evaluated for cytotoxicity using human cancer cell lines 
following the MTT assay, but no evidences of acute cytotoxicity were found (Ng et 
al., 2010). Similar finding was also observed in another study (Srinivasulu, 1992), 
where no acute toxicity was observed at the pharmacological doses administered. 
The LD50 of the aqueous extract was > 5000 mg / kg body weight (Asare et al., 2011). 
In a later study, the ethanol extract of P. niruri was not cytotoxic or genotoxic and 
generally non-toxic on subchronic administration (Asare et al., 2012). 
 
1.1.3 Lignans in Phyllanthus niruri 
Modern scientific research indicated that the lignans are phenolic compounds 
existing in many plants (Willfor et al., 2006). Studies on dietary phytoestrogens also 
revealed that the lignans also existed in food (Kuhnle et al., 2008). 
 
1.1.4 Pharmacological properties of lignans 
Attention was focused on the lignans because of the vast potential biological 
activities (Willfor et al., 2006). The lignans in P. niruri have anti-hepatitis B virus 
activities (Wei et al., 2012), anti-angiogenic activity (Ng et al., 2010), anti-tumour 
effects (Islam et al., 2008), anti-inflammatory and anti-allodynic actions (Kassuya et 
al., 2006), hepatoprotective effect (Nguyen and Tran, 2004), and anti-oedematogenic 
properties (Kassuya et al., 2003), etc. A recent research indicated that a lignan-rich 
fraction of P. niruri MeOH extract was able to reduce the plasma uric acid level of 
hyperuricemic rats comparable to that of clinically-used drugs. Phyllanthin, 
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hypophyllanthin, and phyltetranlin, were involved in the anti-hyperuricemia activity 
(Murugaiyah and Chan, 2006) due mainly to their uricosuric action and partly 
through the xanthine oxidase inhibition (Murugaiyah and Chan, 2006, 2009). 
 
1.2 Male infertility and Eurycoma longifolia 
 
1.2.1 Male infertility and medicinal approaches. 
According to the World Health Organization (WHO), infertility is the “inability to 
conceive a child.” A couple may be considered infertile if after two years of regular 
sexual intercourse without contraception, the woman has no development of 
pregnancy. Male infertility is the inability to achieve a pregnancy in a fertile female. 
In humans, male infertility accounts for 40 % to 50 % of infertility (Brugh and 
Lipshultz, 2004). More than 90 % of male infertility are due to low  sperm count and 
quality (Bhasin et al., 1994). Social problems as well as psychological distress, 
according to Greil, may be caused by infertility (Greil, 1997, Schmidt et al., 2005). 
 
The combination of clomiphene citrate and vitamin E was used for the treatment of 
idiopathic oligoasthenozoospermia by improving sperm count and sperm motility 
(Ghanem et al., 2009). The semen count could be ameliorated by treatment with low 
doses of testosterone and estrogen (Sah, 1998). While assisted reproductive 
technologies, such as IVF (in vitro fertilization) are available, there are several 
disadvantages that are associated with these approaches, such as multiple birth, side 
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effects from fertility drugs, ectopic pregnancy, etc. Barriers also exist in terms of 
medical affordability. 
 
1.2.2 Eurycoma longifolia 
 
1.2.2 (A) Botanical aspects and traditional usage 
E. longifolia Jack, from the Simaroubaceae family, is known locally as “Tongkat Ali”. 
E. longifolia is a tropical herbal plant found in Indonesia and Vietnam and widely 
grows in Malaysia (Perry and Metzger, 1980). The four species of Tongkat Ali are 
Eurycoma longifolia, Entomophthora apiculata, Polyathia bullata, and 
Goniothalamus sp (Bhat and Karim, 2010). Amongst them, Eurycoma longifolia is 
the most commonly used species for traditional medicine (Athimulam et al., 2006). 
Traditionally, the plant was used in Malaysia to increase male virility and sexual 
prowess during sexual activities (Ang and Cheang, 2001). Scientific research has 
confirmed this curative effect (Ang et al., 2000, Ang and Lee, 2002, Bhat and Karim, 
2010). 
 
1.2.2 (B) Chemical constituents and activities 
Several constituents have been identified from the plant. These constituents are 
quassinoids (Ang et al., 2002, Miyake et al., 2009, Teh et al., 2009), canthin-6-one 
alkaloids (Mitsunaga et al., 1994, Miyake et al., 2010), β-carbolines alkaloids (Kuo 
et al., 2003, Miyake et al., 2010), tirucallane-type triterpenes (Itokawa et al., 1992), 
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squalene derivatives (Morita et al., 1993), biphenylneolignans (Morita et al., 1992) 
anthraquinones, anthraquinone glucosides and oxasqualenoid (Miyake et al., 2010). 
The alkaloids and quassinoids comprise the major constituents of this plant (Hou et 
al., 2011). 
 
1.2.2 (C) Toxicology and safety 
Although E. longifolia is widely used, published studies regarding its toxicity are 
scarce. The methanol, chloroform, n-butanol, and aqueous extracts of E. longifolia 
were studied  for cytotoxicities (Chan et al., 1986). In another study, tests on normal 
cells indicated that these root extracts were not toxic or harmful (Nurhanan et al., 
2005). A recent unpublished safety assessment was performed (Low, 2005) that 
included the acute, sub-chronic, chronic, reproductive toxicology, and teratological 
studies of the standardized quassinoid-rich E. longifolia extract in rats. The doses 
when extrapolated to humans were safe for use. In a most recent research, the in vitro 
evaluation of human spermatozoa samples for the toxicity study found that the 
therapeutic concentration of E. longifolia extract have no harmful effects (Erasmus et 
al., 2012). 
 
1.2.3 Quassinoids in Eurycoma longifolia 
Quassinoids are bitter constituents of Simaroubaceae, first structurally identified and 
isolated from Quassia amar (Curcino Vieira et al., 2006). These compounds are also 
isolated from Ailanthus vilmoriniana (Takeya et al., 1997), Quassia indica (Koike 
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and Ohmoto, 1994), and Eurycoma longifolia (Chan et al., 1989, Jiwajinda et al., 
2001, Ang et al., 2002, Miyake et al., 2009). 
 
1.2.4 Pharmacological properties of quassinoids 
Quassinoids have anti-proliferative effects on cancer cell lines (Wong et al., 2012). 
Quassinoids also possess activities that are anti-estrogenic (Teh et al., 2011), anti-
malarial (Kardono et al., 1991, Chan et al., 2004, Chan et al., 2005), anti-ulcer (Tada 
et al., 1991), anti-tumour promoting, anti-parasitic (Jiwajinda et al., 2002), and anti-
leukemic (Itokawa et al., 1992). 
 
A recent research found that a quassinoid-rich E. longifolia MeOH extract 
significantly improved the sperm count of male rats (Chan et al., 2008a, 2009). This 
plant may potentially be suitable for the management of male infertility (Chan et al., 
2009). Another research group confirmed this finding. The study indicated that E. 
longifolia could be a potential agent for reversing the effects of estrogen by 
increasing spermatogenesis and sperm count in rats (Wahab et al., 2010). 
 
1.3 Biopharmaceutical Classification System (BCS) 
Previous studies on the bioactive lignans in P. niruri and quassinoids in E. longifolia 
extracts found poor oral bioavailabilities (Low et al., 2005, Murugaiyah and Chan, 
2007). In view of future formulation development, the bioactive compound-rich 
extracts could be first classified by using the biopharmaceutical classification system 
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(BSC) (Table 1-1). This system classified the drug substances in four classes 
according to membrane permeability and water solubility (Lobenberg and Amidon, 
2000). With references to previous studies, the lignan-rich P. niruri extract could be 
classified as a BSC class Ⅱ type, possessing high permeability and low solubility. 
The quassinoid-rich E. longifolia extract could be classified as a BSC class Ⅲ type 
that has low permeability and high solubility. These categories provide a significant 
indicator for the formulation strategies that should be adopted to improve the oral 
bioavailabilities.  
 
Table 1-1 Biopharmaceutical classification system. 
Class Permeability Solubility 
Ⅰ High High 
Ⅱ High Low 
Ⅲ Low High 
Ⅳ Low Low 
 
 
1.4 Conventional solid oral dosage forms 
Oral drug delivery is a simple and easy way to administer drugs (Sugawara et al., 
2005). Solid oral dosage forms (such as powders, granules, tablets, and capsules) 
have several advantages compared with other oral dosage forms (Vasconcelos et al., 
2007), in terms of chemical stability, accurate preparation procedure, low 
manufacturing cost, effectively mask unpleasant taste, and easily be  commercially 
used for oral delivery, etc. Although powders and granules have relatively faster 
dissolution rates compared with tablets and capsules, some disadvantages limit their 
 10 
use. For instance, they are inconvenient for patients to carry, and masking their 
unpleasant tastes may be a problem as well. In addition, some drugs are not suitable 
for oral administration as powder and granules may be damaged by the acidic 
stomach. The tablet, as one of the most popular oral dosage forms, could overcome 
these problems. Firstly, the preparation procedure for tablets leads to accurate dose 
amount of the drug in each piece. Secondly, tablets are convenient to handle, and are 
prepared according to their use and delivery. In addition, tablets can be produced and 
provided as preparations of very low price with consistent quality. 
 
Another popular dosage form is capsules. Capsules are usually made of gelatin and 
are filled with medicinal substances. The gelatin capsule could be easily dissolved in 
the stomach and has been scientifically proven as safe raw material (Jones, 2002). 
Gelatin capsules could be categorized as hard and soft.  Variety of solid and 
semisolid materials could be filled in the hard gelatin capsules, whereas liquid and 
semisolid materials could be filled in soft gelatin capsules. Thus, modified release 
can also be achieved using capsules, and the most commercially available lipid-based 
oral formulations are capsules (Strickley, 2007). The extended shape and smooth 
surface of the capsule shell are made for improving patient compliances. In addition, 
the capsules could effectively mask unpleasant odour and taste, therefore suitable for 
clinical studies (Podczeck, 2004). Moreover, hard capsules require shorter 
manufacturing process compared with tablets.  
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1.5 Alternative dosage forms 
Conventional formulations, such as physical mixing of actives with excipients, may 
not effectively increase the bioavailability of many active compounds belonging to 
BSC II, III, and IV drugs. Thus, other safe and effective formulation methods need to 
be considered. Cyclodextrin complexations, liposomes, nanoparticles, and solid 
dispersions could be used as alternative options because they efficiently improve the 
bioavailability of entrapped compounds, have less or non-toxic character and possess 
wider application.  
 
1.5.1 Cyclodextrin complexation 
Cyclodextrins (CD) are cyclic oligosaccharides of D-glucose residues attached by 
(R-1,4)-linkages, which can be described as a cone shape molecule. They consist of  
relatively hydrophobic interior and hydrophilic exterior (Clarke et al., 1988) (Figure 
1-1). Out of many CDs and derivatives available, the three widely used are α-, β-, 
and γ-cyclodextrin (α-CD, β-CD, and γ-CD), which consist of six, seven, and eight 
D-glucose units, respectively. 
 
                                            Figure 1-1. Cyclodextrins    
(http://www.chemiedidaktik.uni-wuppertal.de/disido_cy/cyen/info/03_physical_cy.htm) 
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The relative nonpolar cavity is the result of the framework of carbons and ethereal 
oxygens, which lined the cyclodextrin molecule (Loftsson and Brewster, 1996). 
Furthermore, the cavity is also lined with secondary dihydroxyl groups that are less 
polar than the outer primary alcohols. Thus, the inner less polar cavity promotes 
hydrogen bonding with polar compounds. The outer primary alcohols provide the 
aqueous solubility. Therefore, the CDs could be utilized as carriers to encapsulate 
bioactive nonpolar compounds to improve their solubility and absorption. As a 
strategic method, numerous formulation studies focus on the CDs. Nevertheless, 
cyclodextrins have some limitations. Firstly, some CDs especially β-CD are 
potentially toxic and has low solubility (Dilova et al., 2004). Derivates of CDs are 
normally applied by synthesis from natural CDs. The application may increase the 
cost of the development process. Secondly, the formation of CD complexes depends 
on the compatibility of the compound size and dimensions of the cavity of the CDs 
as well as the geometrical shapes of guest compounds (Cohen and Lach, 1963). No 
correlations exist between the physical or chemical properties of guest compound 
and the complexation ability with CDs. Thirdly, the complexation efficiency of CDs 
are low; hence, a relatively large amount of CDs is normally required to achieve the 
desired entrapment efficiency when preparing the complex, before the desired 
solubility could be achieved (Loftsson et al., 1999). Fourthly, highly water-soluble 
compounds cannot be complexed because of the interior and exterior polar properties 
of CDs. Fifthly, the high melting point compounds are generally entrapped weakly in 
CDs. Sixthly, only a limited amount of compounds can be practically carried because 
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CDs have large molecular weights. Finally, when preparing the complexation, the 
complexing agent may alter the toxicity of the drug. Thus, additional toxicity study 
needs to be conducted. The cost of drug development and manufacturing should also 
be considered as well (Wei, 2008). 
 
1.5.2 Liposomes 
 
 
Figure 1-2. Liposome. (Liu, 2008) 
 
As drug carrier, liposomes could improve the delivery of therapeutic compounds. 
They are micro-spherical vesicles that consist of phospholipid bilayers surrounding 
an aqueous space. They are biocompatible materials with varying diameter from 0.02 
to 10 μm (Sharma and Sharma, 1997, Drulis-Kawa and Dorotkiewicz-Jach, 2009). 
 
The liposomal drug could target the site of disease. This behavior can be attributed to 
the increased spaces of capillary endothelial cells of the disease states (Ostro and 
Cullis, 1989, Bangham, 1992). The drug compounds could efficiently target the 
disease tissue, and could increase drug potency and reduce toxicity (Liu, 2008). 
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The release of the entrapped drug compounds in liposomes is achieved by plasma 
proteins (example lipoprotein) that degrade the liposome. In this process, the lipid 
bilayer structure is destroyed by the removal of phospholipids molecules. The 
unstable lipid bilayer structure will then release the entrapped drug into the plasma 
circulation. Therefore, the liposome acts as a drug reservoir offering sustained 
release that is more suitable for parenteral dosage forms (Liu, 2008). The oral 
administrated liposomes are easily digested by phospholipids and bile salts in the 
GIT.  
 
Although liposomes are mainly used for target release by parenteral administration, 
the oral administrations of liposomal formulation were also reported for both polar 
and nonpolar compounds because of the unique structure of the liposomes (Micklus, 
1991). For the oral formulations, polar compounds can be entrapped in a central 
aqueous cave of liposomes, whereas nonpolar compounds are ensnared in the lipid 
bilayer (Figure 1-2). However, the mechanism of this oral administration of 
liposomes is similar to other lipid-based oral drug delivery system (Gregoriadis et al., 
1990, Liu, 2008). Thus, liposomes as oral delivery carrier have no particular 
superiority compared with other lipid-based oral drug delivery system. 
 
Liposomes are excellent materials for drug formulation because they can encapsulate 
the wide range of active compounds regardless of size, shape, and polarity. However, 
liposomes normally possess comparatively lower entrapment capacity of water-
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soluble compounds because of lower lipid/aqueous distribution ratio. In addition, the 
procedures to entrap the water soluble compounds in liposomes are more 
complicated than water insoluble compounds (Liu, 2008). 
 
The stability of liposome formulation is another important issue that needs to be 
considered when designing the formulation because the phospholipids are the major 
materials in forming the liposome. Hydrolysis and oxidative degradation of 
phospholipids could significantly affect the liposome physical and chemical 
properties, and subsequently changes the bilayer fluidity, permeability, and 
encapsulation efficiency. 
 
1.5.3 Nanoparticles 
Nanoparticles can be achieved by using two methods, namely, mechanical and 
chemical processes. Mechanical processes produce the particles in a range of 100 to 
1000 nm, whereas chemical processes can produce 10 to 100 nm particles (Acosta, 
2009). Theoretically, the reduction of the particle size by mechanical processes 
results in an increase in the surface area, which subsequently improves the solubility 
of the drug and increase absorption. Nevertheless, for those insoluble and sparingly 
soluble compounds, the potency of this method is limited. In the case of chemical 
processes, chemical reactions or solubilizing agents are involved (Lee, 2008, Acosta, 
2009). However, in some cases, the bioavailability may not be proportional to the 
particle size. Practical data reveal that the active ingredients in the range of 100 to 
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1000 nm could improve bioavailability (Acosta, 2009). In addition, materials with 
very small particle size ( < 2 μm) are not easy to handle for manufacturing of dosage 
forms (Vasanthavada, 2008). 
 
In the pharmaceutical field, nanoparticles are mainly applied as vehicles to improve 
the absorption of poor water soluble compounds and are also widely used as 
sustained, controlled, and target release formulations (Calvo et al., 2001, Zhang et al., 
2006, Du et al., 2010, Zhang et al., 2011). Some researchers suggest in principle that 
nanoparticles could deliver polar nutraceutical compounds, such as isoflavones 
(Ratnam et al., 2006, Acosta, 2009). Nevertheless, improvements of the absorption of 
these polar compounds may be due to the nanoparticles coat with lectins (Acosta, 
2009), which are non catalytic sugar-binding proteins that act as bioadhesins in 
attaching to the epithelial lining at mucosal surfaces. Thus, this attachment could 
reduce the dilution, wash-off active compounds at the epithelial lining, and enhance 
the absorption (Clark et al., 2000, Ohno et al., 2005). Other researchers reported the 
preparation of water soluble drug nanoparticles by the precipitation method. 
However, the entrapment efficiency is poor (Cheow and Hadinoto, Barichello et al., 
1999, Govender et al., 1999). Several applications of nanoparticles for the 
improvement of polar compounds are actually microemulsion-based, which could 
reduce the emulsified droplet size to less than 100 nm (Pouton, 2000). This 
procedure could also achieve high efficiency by designing a self-microemulsifying 
drug delivery system (SMEDDS) that uses lipids and/or surfactants. 
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1.5.4 Solid dispersions 
Solid dispersions are robust methods to improve oral bioavailability of poorly soluble 
drugs (Vasconcelos et al., 2007). Solid dispersion refers to the dispersion of active 
compounds in an inert matrix at solid state (Chiou and Riegelman, 1971). Recent 
studies show that the dispersion involves the forming of well-proportioned physical 
or molecular mixture of active drug compounds and water soluble carriers at eutectic 
temperature (Goldberg et al., 1966, Vasanthavada, 2008). This method may also 
entrap the active compounds in carriers as amorphous materials. Often, it is a 
combination of amorphous, physical and molecular mixture (Mayersohn and Gibaldi, 
1966, Vasanthavada, 2008, Newman et al., 2012). Therefore, solid dispersions could 
form effective oral formulations without being fully solubilized in the excipient 
matrix. The theory of this system is to increase the dissolution rate. The increase may 
be due to reduction of drug particle size, absence of aggregation of drug crystallites, 
improvement of the wetting ability of the drug, and creation of the drug compound in 
an amorphous state, or the combination of these theories (Ford, 1986, Damian et al., 
2000). 
 
For the poor water soluble drugs, the solubility and the permeability are the restraint 
steps for absorption. Although the nonpolar compounds in most cases possess high 
permeability, the small absorption window of the GIT in certain cases may restrict 
absorption in certain cases (Junghanns and Muller, 2008). Thus, using solid 
 18 
dispersions in increasing solubility is one of the effective strategies in solving this 
problem. In the bench top scale, fusion and solvent evaporation are two commonly 
used methods. 
 
The first generation of solid dispersions using crystalline carriers such as urea and 
sugars were thermodynamically stable, but did not release the drugs quickly (Kanig, 
1964, Sekiguchi et al., 1964). Instead, crystalline amorphous materials were used in 
the second generation, since these materials do not affect the dissolution process 
(Taylor and Zografi, 1997, Pokharkar et al., 2006). In recent years, the third 
generation solid dispersion system was broadly applied in research and 
manufacturing. This generation contained surfactants or a mixture of amorphous 
polymers and surfactants as carriers, which have surface activities and self-
emulsifying properties. Gelucire
®
 is one group of carriers belonging to the third 
generation of solid dispersions (Karatas et al., 2005). Solid dispersions are widely 
used in the pharmaceutical formulations because of several advantages such as 
patient compliance for administration, convenient storage, more stable compared 
with liquid dispersions, and application to a wide range of compounds. The reduced 
particle size may reach molecular level as well. 
 
Although many privileges are associated with solid dispersions, some disadvantages 
exist for this formulation. The disadvantages include less ability to scale up the 
formulation from bench top to manufacturing level. However, some pharmaceutical 
 19 
companies (such as Fuji Chemical Industry) and techniques (such as hot melt 
extrusion and encapsulation, spray drying, and supercritical fluid) have already 
successfully scaled up some solid dispersion methods to some extent. Among them, 
hot melt encapsulation is a suitable method for Gelucires
®
 to fill the capsules. Thus, 
this technique results in a simplified manufacturing procedure. In addition, the 
equipment to scale up this method to commercial-grade is already available 
(Vasanthavada, 2008). 
 
1.5.5 Other formulation approaches 
Some other pharmaceutical formulation methods to improve the bioavailability of 
active drug ingredients are also available such as emulsions, salt formation, and 
mechanical methods to reduce particle size. However, these methods all have 
limitations and may not be practical for using and manufacturing (Serajuddin, 1999, 
Neslihan Gursoy and Benita, 2004). For example, emulsions are not in solid forms, 
and have stability problems. Salt formations are not applied for neutral compounds, 
and they may be converted into acidic or basic forms in vivo. A reduced particle size 
may cause poor flow ability and adhesion during manufacturing. 
 
1.6 Gelucire® solid dispersions 
 
1.6.1      Gelucire® 
Gelucire
®
 is a group of excipients that are widely used in solid dispersions. The 
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drugs incorporated in these solid dispersions can have their bioavailabilities 
increased (Svensson et al., 2004). They are semi-solid, waxy material with 
amphiphilic properties (Yuksela et al., 2003). Gelucire
®
 are a family of 
polyglycolised glyceride bases, which consist of polyethylene glycol (PEG) esters of 
various fatty acids, tri-, di-, and mono-glycerides of the fatty acids, with some of the 
corresponding free fatty acids and PEGs present in small quantities (Khan and Craig, 
2003). It is inert, safe, non-toxic, and has been reported to be chemically stable in 
temperature and humidity of up to 50 °C and 80 % RH, respectively (Remuan et al., 
1992).  
 
Gelucire
®
 is characterized by two values, which are hydrophile-lipophile-balance 
(HLB) and melting point. The numeral values reflect a specific physical character, 
when solid dispersions of Gelucires are placed in the gastrointestinal fluids, such as 
hydrodispersibility, melting, and floatability (Doelker et al., 1986). The nominal 
melting point, which ranges from 33 °C to 70 °C, can only be used as a reference. 
This value does not represent the accurate melting point of the base. Many 
compounds exist in Gelucire
®
 products; thus, a single and sharp melting point could 
not be identified for Gelucire
®
. The HLB value of Gelucire
®
 ranges from 1 to 18. 
The Gelucire
®
 product with a higher HLB value showing hydrophilic property is 
appropriate for the formulation of fast-release dosage forms. It tends to produce oil-
in-water (o/w) emulsions, when the Gelucire
®
 based product contact the GIT fluids. 
In contrast, the Gelucire
®
 base with lower HLB values having higher portions of 
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lipophilic fractions are suitable for formulating controlled release formulations, and 
tend to produce water-in-oil (w/o) emulsions (Baykara and Yuksel, 1991, San Vicente 
et al., 2000, Karatas et al., 2005). The amphiphilicity of the base conferred by the 
long hydrocarbon chain and the alcohol moieties means that both hydrophilic and 
hydrophobic drugs can potentially be incorporated into these carriers (Choy et al., 
2005). In addition, extremely insoluble drugs tend to re-crystallize upon exposure to 
the gastrointestinal tract during dissolution (Serajuddin, 1999, Leuner and Dressman, 
2000). Semi-solid surfactants, such as Gelucire
®
, have the potential to facilitate 
dissolution, and to inhibit precipitation in the GI tract because of their solubilizing 
properties (Yuksel et al., 2003, Soliman and Khan, 2005). Gelucire
® 
44/14 and 
Gelucire
®
50/13 are two most commercially used products that are approved as food 
additives in the USA (Raymond C. Rowe et al., 2012).  
 
The definition of Gelucire
®
44/14 and Gelucire
®
50/13 can be found in the Handbook 
of Pharmaceutical Excipients.  The chemical name of Gelucire
®
44/14 is lauroyl 
macrogolglycerides (polyoxylglycerides). Lauroyl macrogolglycerides is a mixture 
of monoesters, diesters, and triesters of glycerol, and monoesters and diesters of 
macrogols with a mean relative molecular mass between 300 and 1500. They are 
obtained by the partial alcoholysis of saturated oils, which mainly contain 
triglycerides of lauric acid, by using macrogol, or by esterification of glycerol and 
macrogol with saturated fatty acids, or by mixing glycerol esters and condensates of 
ethylene oxide with the fatty acids of these hydrogenated oils (Rowe et al., 2012). 
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The chemical name of Gelucire
®
50/13 is stearoyl macrogolglycerides 
(polyoxylglycerides). Stearoyl macrogolglycerides are mixtures of monoesters, 
diesters, and triesters of glycerol, and monoesters and diesters of macrogols with a 
mean relative molecular mass between 300 and 4000. They are obtained by partial 
alcoholysis of saturated oils, which contain mainly triglycerides of stearic acid, by 
using macrogol, or by esterification of glycerol and macrogol with saturated fatty 
acids, or by a mixture of glycerol esters and condensates of ethylene oxide with the 
fatty acids of these hydrogenated oils (Rowe et al., 2012). Although similar in 
composition, Gelucire
® 
44/14 forms micro emulsions on contact with the aqueous 
phase, whereas Gelucire
® 
50/13 swells with water and give gradual drug release 
(Khan and Craig, 2003). Thus, Gelucire
® 
44/14 could be used for the formulation of 
fast release, and Gelucire
® 
50/13 for controlled or sustained release. Gelucire
®
 could 
also be filled into the capsules, which will simplify manufacturing procedures (Tang 
et al., 2008).  
 
1.6.2 Gelucire® 44/14 
 
Gelucire
® 
44/14 (G44/14) refers to the Gelucire
® 
excipients that are commercially 
used (Fernandez et al., 2008). G44/14 comprises about 72 % PEG esters, 20 % 
glycerides, 8 % pure PEG and 2 % glycerol (Svensson et al., 2004). Gelucire
®
 is 
known to be safe at LD50 (rat, oral) > 2004 mg/kg/day (Chambin and Jannin, 2005, 
Raymond C. Rowe et al., 2012). The G44/14 is characterized by the hydrophile-
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lipophile-balance (HLB) value (14) and melting point (44) which leads to a specific 
behavior when placed in the gastrointestinal fluids (Vial-Bernasconi et al., 1995). 
 
When G44/14 is released in the GIT, it will dissolve in the dissolution medium and 
form milky dispersions. Subsequently, an o/w micro or nano emulsion will form. 
Thus, the solubility of the nonpolar compounds could be increased. This condition 
may be explained by the increased wettability and micellar solubilization (Figure 1-
3). However, G44/14 as a self-emulsifying microemulsion is superior to simple 
micellar solutions in terms of solubilization potential and their thermodynamic 
stability. G44/14 increased bioavailability was also reported to be associated with 
strong inhibition of the enterocytic efflux transporter (known as P-gp inhibition) and 
strong inhibition of the enterocytic drug metabolizing enzyme, CYP3A4 (Wandel et 
al., 2003, Cornaire et al., 2004, Jannin et al., 2008).  
 
 
Figure 1-3. Micelles o/w and w/o 
http://www2.umt.edu/medchem/teaching/medchem/mclect2.htm 
 
For the microemulsions, the nonpolar compounds are suitable to prepare the o/w 
form, whereas polar compounds are appropriate for the w/o system. The HLB value 
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could be an indicator to demonstrate the tendency of w/o and o/w forms. The use of 
combined emulsifiers with low and high HLB values may produce a more rapid 
dispersion and finer emulsion droplet on contact with water. Cannon (2008) indicated 
that a w/o emulsion could be formed since the water would be taken up into the 
formulation at the beginning of dilution. Other researchers also reported the 
preparation of a mixture of emulsifiers to achieve certain release profiles (Tran et al., 
2009). The incorporation of G50/13 and G50/02 by Dennis et al. (1990) increased 
the in vitro release of ketoprofen. 
 
Nevertheless, the release mechanism of drug microemulsions (both w/o and o/w) 
from the lipid-based self-emulsifying drug delivery systems is not yet well 
understood. However, micelles facilitated delivery is generally accepted (Charman et 
al., 1997). Other possibilities include the inhibition of the pre-system metabolism, 
efflux of P-gp, and lymphatic transport (O'Driscoll, 2002, O'Driscoll and Griffin, 
2008). For G44/14, it is difficult to predict the release behavior (Choy et al., 2005). 
The improved absorption may be due to the surface activities, or a combination of 
the self-emulsifying mechanisms (Tran et al., 2009). 
 
1.7 Oral absorption and bioavailability 
Drug bioavailability is the ratio of the amount of the unchanged drug reaching the 
circulation system after administration of a dosage form (Levy et al., 1969). Oral 
drug bioavailability is the extent that the drug molecules could be absorbed in the 
